Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ziad Taweh

Internal Medicine Danbury, CT Medical Doctor

NPI 1447282223 CMS profile 859585

27 Hospital Ave, Suite 403, Danbury, CT 06810

Open in the dashboard

General payments

$4,133

226 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ziad Taweh of Danbury, CT is reported in the CMS Open Payments database as having received $4,133 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $506 24
2024 General $623 32
2023 General $513 26
2022 General $777 46
2021 General $941 51
2020 General $358 19
2019 General $414 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ziad Taweh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ziad Taweh were reported at $506. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ziad Taweh Internal Medicine median Middle half National median
2019 $414 $159 $48–$570 $163
2020 $358 $119 $33–$402 $114
2021 $941 $135 $37–$521 $132
2022 $777 $141 $42–$496 $149
2023 $513 $149 $45–$519 $160
2024 $623 $154 $47–$537 $164
2025 $506 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,456 77 payments
  2. AstraZeneca Pharmaceuticals LP $358 19 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $332 17 payments
  4. Pfizer Inc. $312 17 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $231 22 payments
  6. Sanofi-Aventis U.S. LLC $209 11 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $162 6 payments
  8. Eisai Inc. $160 10 payments
  9. Novartis Pharmaceuticals Corporation $120 6 payments
  10. Abbott Laboratories $93 4 payments
  11. Other $701 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,133 226 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $620 39 payments
  2. QULIPTA $445 22 payments
  3. UBRELVY $410 21 payments
  4. NURTEC ODT $247 13 payments
  5. ELIQUIS $246 13 payments
  6. BREZTRI $217 11 payments
  7. TRINTELLIX $180 14 payments
  8. SPIRIVA RESPIMAT $168 9 payments
  9. JARDIANCE $162 8 payments
  10. Kerendia $162 6 payments
  11. Other $2,213 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

3,107

Median for Internal Medicine: 777

Drug cost

$265,535

Median for Internal Medicine: $73,373

Branded share of claims

21.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 76 $82,551
Mounjaro Tirzepatide Brand 38 $40,578
Januvia Sitagliptin Phosphate Brand 20 $32,318
Jardiance Empagliflozin Brand 18 $29,758
Rexulti Brexpiprazole Brand 12 $20,485
Eliquis Apixaban Brand 13 $19,338
Atorvastatin Calcium Generic 248 $2,404
Albuterol Sulfate Hfa Albuterol Sulfate Brand 55 $2,288
Losartan Potassium Generic 159 $1,783
Levothyroxine Sodium Generic 150 $1,754

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$75,076

Of which drugs: $1,165

Medicare patients

177

Average age 75

Services billed

977

94 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 47%
Ischemic heart disease 23%
Depression 20%
Chronic kidney disease 18%
Atrial fibrillation 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 18 18 $650

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $117
$117 — —
VRAYLAR
  • AbbVie, Inc. $86
$86 — —
QULIPTA
  • AbbVie, Inc. $84
$84 — —
NURTEC ODT
  • PFIZER INC. $68
$68 — —
ELIQUIS
  • PFIZER INC. $49
$49 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record